Display options
Cite
Merkt W, Salzer U, Thiel J, et al. Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides. BMC Immunol. 2021;22(1):26doi: 10.1186/s12865-021-00416-w.
Merkt, W., Salzer, U., Thiel, J., Jandova, I., Bergner, R., Venhoff, A. C., & Venhoff, N. (2021). Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides. BMC immunology, 22(1), 26. https://doi.org/10.1186/s12865-021-00416-w
Merkt, Wolfgang, et al. "Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides." BMC immunology vol. 22,1 (2021): 26. doi: https://doi.org/10.1186/s12865-021-00416-w
Merkt W, Salzer U, Thiel J, Jandova I, Bergner R, Venhoff AC, Venhoff N. Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides. BMC Immunol. 2021 Apr 12;22(1):26. doi: 10.1186/s12865-021-00416-w. PMID: 33840389; PMCID: PMC8040212.
Copy Download .nbib Format: NLM
Share it on

BMC Immunol. 2021 Apr 12;22(1):26. doi: 10.1186/s12865-021-00416-w.

Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides.

BMC immunology

Wolfgang Merkt, Ulrich Salzer, Jens Thiel, Ilona Jandova, Raoul Bergner, Ana C Venhoff, Nils Venhoff

Affiliations

  1. Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. [email protected].
  2. Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  3. Department of Rheumatology, Nephrology, Haemato-Oncology, Klinikum Ludwigshafen, Ludwigshafen, Germany.
  4. Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany. [email protected].

PMID: 33840389 PMCID: PMC8040212 DOI: 10.1186/s12865-021-00416-w

Abstract

BACKGROUND: Cytotoxic Natural Killer (NK) cells are increasingly recognized as a powerful tool to induce targeted cell death in cancer and autoimmune diseases. Still, basic blood NK cell parameters are poorly defined. The aims of this study were 1) to establish reference values of NK cell counts and percentages in healthy adults; 2) to describe these parameters in the prototype autoimmune disease group ANCA-associated vasculitis (AAV); and 3) to investigate whether NK cell counts and percentages may be used as activity biomarkers in the care of AAV patients, as suggested by a preceding study.

METHODS: CD3-(CD56 or 16)+ NK cell counts and percentages were determined in 120 healthy adults. Lymphocyte subset and clinical data from two German vasculitis centers were analyzed retrospectively (in total 407 measurements, including 201/49/157 measurements from 64/16/39 patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), respectively).

RESULTS: CD3-(CD56 or 16)+ NK cell counts and percentages in healthy adults were highly variable, not Gaussian distributed and independent of age and sex. NK cell percentages ranged from 1.9 to 37.9% of lymphocytes, and were significantly more dispersed in AAV (0.3 to 57.6%), while the median percentage was not different between AAV and healthy donors. In contrast, median NK cell counts were significantly lower in AAV compared to healthy donors. Sub-group analyses revealed that NK cell counts were low independent of AAV entity and disease activity. Azathioprine therapy was associated with significantly lower NK cell counts and percentages compared to non-azathioprine therapies. In 13.6% of azathioprine-treated patients, percentages were

CONCLUSIONS: NK cell counts and percentages in blood are heterogeneous and can presently not be recommended as biomarker in clinical care of AAV patients. Azathioprine treatment was associated with significantly low NK cells. These findings may be relevant for the development of drugs that aim at exploiting NK cell cytotoxicity and may help to identify patients at risk to develop malignant or infectious co-morbidities.

Keywords: ANCA-associated vasculitis; Azathioprine; Natural killer cells

References

  1. Arthritis Res Ther. 2015 Nov 21;17:337 - PubMed
  2. World J Gastroenterol. 2017 May 14;23(18):3240-3251 - PubMed
  3. Blood. 2007 Jul 15;110(2):606-15 - PubMed
  4. Am J Transplant. 2016 Dec;16(12):3490-3503 - PubMed
  5. J Allergy Clin Immunol. 2013 Sep;132(3):515-525 - PubMed
  6. Arthritis Res Ther. 2016 Sep 15;18(1):206 - PubMed
  7. Eur J Immunol. 2004 Oct;34(10):2930-40 - PubMed
  8. Data Brief. 2017 Apr 21;12:400-404 - PubMed
  9. Am J Gastroenterol. 2010 Jul;105(7):1604-9 - PubMed
  10. Eur J Immunol. 2017 Oct;47(10):1584-1797 - PubMed
  11. Nat Rev Rheumatol. 2014 Aug;10(8):484-93 - PubMed
  12. Blood. 2013 Jun 6;121(23):4694-702 - PubMed
  13. Nat Rev Gastroenterol Hepatol. 2009 Aug;6(8):444-5 - PubMed
  14. Arthritis Res Ther. 2017 May 18;19(1):101 - PubMed
  15. Nat Rev Drug Discov. 2020 Mar;19(3):200-218 - PubMed
  16. Blood. 2010 Jun 3;115(22):4393-402 - PubMed
  17. Ageing Res Rev. 2013 Sep;12(4):1069-78 - PubMed
  18. Aliment Pharmacol Ther. 2009 May 15;29(10):1106-13 - PubMed
  19. Nat Rev Rheumatol. 2016 Oct;12(10):570-9 - PubMed
  20. J Clin Immunol. 1989 May;9(3):214-22 - PubMed
  21. Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9626-E9634 - PubMed
  22. Nat Rev Rheumatol. 2019 Feb;15(2):91-101 - PubMed
  23. Nature. 2019 Oct;574(7776):45-56 - PubMed
  24. Arthritis Res Ther. 2019 Dec 11;21(1):277 - PubMed
  25. Aging Cell. 2010 Aug;9(4):527-35 - PubMed
  26. Aging Cell. 2012 Oct;11(5):751-9 - PubMed
  27. Eur J Haematol. 2004 Mar;72(3):203-12 - PubMed
  28. N Engl J Med. 2014 Mar 20;370(12):1101-10 - PubMed
  29. Cell Death Differ. 2014 Jan;21(1):5-14 - PubMed
  30. Blood. 2011 Sep 22;118(12):3347-9 - PubMed
  31. J Immunol. 2011 Apr 15;186(8):4590-8 - PubMed
  32. Nat Immunol. 2008 May;9(5):503-10 - PubMed
  33. Arthritis Res Ther. 2016 Sep 13;18(1):204 - PubMed
  34. Ann Rheum Dis. 2007 May;66(5):605-17 - PubMed
  35. J Clin Invest. 2012 Mar;122(3):798-801 - PubMed
  36. Am J Epidemiol. 2013 Jun 1;177(11):1296-305 - PubMed
  37. Aliment Pharmacol Ther. 2011 Jan;33(1):115-26 - PubMed
  38. Curr Opin Rheumatol. 2014 Jan;26(1):24-30 - PubMed
  39. J Leukoc Biol. 2004 Aug;76(2):291-9 - PubMed
  40. N Engl J Med. 2010 Jul 15;363(3):221-32 - PubMed

Publication Types